Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F E Davies

Showing results (1-10 of 57) with videos related to

Pageof 6
Sort By:
British Journal of Cancer|January 19, 2005
Evolving treatment strategies for myelomaG J Morgan, F E Davies
European Journal of Haematology|July 20, 2000
Novel therapeutic targets in multiple myelomaF E Davies, K C Anderson
Clinical Molecular Pathology|August 1, 1996
Karyotypic and molecular abnormalities in chronic lymphocytic leukaemiaC D Fegan, F E Davies
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|August 30, 2002
Myeloma aetiology and epidemiologyG J Morgan, F E Davies, M Linet
British Journal of Haematology|January 31, 1998
The use of biological variables to predict outcome in multiple myelomaF E Davies, A S Jack, G J Morgan
Clinical and Laboratory Haematology|August 2, 2003
The use of genetic microarray analysis to classify and predict prognosis in haematological malignanciesA P Levene, G J Morgan, F E Davies
Clinical and Laboratory Haematology|April 1, 2004
Proteomics and the haematologistK S Rees-Unwin, G J Morgan, F E Davies
Expert Opinion on Drug Safety|February 26, 2016
The safety of pomalidomide for the treatment of multiple myelomaJ R Jones, C Pawlyn, F E Davies, et al.
British Journal of Haematology|August 10, 2000
Controversies surrounding the clonogenic origin of multiple myelomaF E Davies, A C Rawstron, R G Owen, et al.
International Journal of Laboratory Hematology|January 15, 2008
Position statement on the use of bortezomib in multiple myelomaG J Morgan, F E Davies, J D Cavenagh, et al.
Pageof 6

Showing results (1-10 of 57) with videos related to

Sort By:
Pageof 6
British Journal of Cancer|January 19, 2005
Evolving treatment strategies for myelomaG J Morgan, F E Davies
European Journal of Haematology|July 20, 2000
Novel therapeutic targets in multiple myelomaF E Davies, K C Anderson
Clinical Molecular Pathology|August 1, 1996
Karyotypic and molecular abnormalities in chronic lymphocytic leukaemiaC D Fegan, F E Davies
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|August 30, 2002
Myeloma aetiology and epidemiologyG J Morgan, F E Davies, M Linet
British Journal of Haematology|January 31, 1998
The use of biological variables to predict outcome in multiple myelomaF E Davies, A S Jack, G J Morgan
Clinical and Laboratory Haematology|August 2, 2003
The use of genetic microarray analysis to classify and predict prognosis in haematological malignanciesA P Levene, G J Morgan, F E Davies
Clinical and Laboratory Haematology|April 1, 2004
Proteomics and the haematologistK S Rees-Unwin, G J Morgan, F E Davies
Expert Opinion on Drug Safety|February 26, 2016
The safety of pomalidomide for the treatment of multiple myelomaJ R Jones, C Pawlyn, F E Davies, et al.
British Journal of Haematology|August 10, 2000
Controversies surrounding the clonogenic origin of multiple myelomaF E Davies, A C Rawstron, R G Owen, et al.
International Journal of Laboratory Hematology|January 15, 2008
Position statement on the use of bortezomib in multiple myelomaG J Morgan, F E Davies, J D Cavenagh, et al.
Pageof 6